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THEORY AND METHODS
Overestimation of complication rates in
evaluations of Chlamydia trachomatis
screening programmes—implications for
cost-effectiveness analyses
Irene GM van Valkengoed,1,2 Servaas A Morré,3,4 Adriaan JC van den Brule,3,5 Chris JLM Meijer,3
Lex M Bouter1 and A Joan P Boeke1
Accepted 4 September 2003
Background Cost-effectiveness analyses of screening programmes for asymptomatic Chlamydia
trachomatis infection suggest that screening at low prevalences in the population
is cost-effective. However, the decision models in these studies are based on
assumptions about the risk of complications, which are derived from the
literature. Incorrect assumptions may lead to under- or overestimation of
the effectiveness of screening. The first objective of this paper is to evaluate the
assumptions about the probability of complications after an asymptomatic
C. trachomatis infection. The second objective is to calculate alternative rates by
using available data on the incidence of complications.
Methods We identified cost-effectiveness studies via Medline, and evaluated these for the
evidence for the quoted probabilities. In addition, the probability of complications
was calculated for Amsterdam from available registration data.
Results In the three studies that were identified, the assumptions for the rates of pelvic
inflammatory disease (PID) (clinical and subclinical) after C. trachomatis infection
varied from 15% to 80%, and for ectopic pregnancy, tubal factor infertility, and
chronic pelvic pain after PID from 5–25%, 10–20%, and 18–30%, respectively.
The assumptions were based on data from high-risk populations, case-control
data, and data not accounting for misdiagnoses. Using data obtained from local
registrations, we estimated the probability of a clinical PID (0.43%), ectopic
pregnancy (0.07%), and tubal factor infertility (0.02%) for women with a
current infection. These estimates were consistently lower than the estimates
based on the literature.
Conclusions We argue that an overestimation of the current complication rates is likely. The
effect of overestimation is potentially the greatest in populations with a low
prevalence, since the currently assumed cost savings associated with screening
may disappear when using more realistic estimates for complications.
Keywords Mass screening, Chlamydia trachomatis, salpingitis, pelvic inflammatory disease,
infertility, costs and cost analysis, ectopic pregnancy
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OVERESTIMATION OF COMPLICATIONS IN C. TRACHOMATIS SCREENING 417
A genital Chlamydia trachomatis infection is the most prevalent
bacterial sexually transmitted infection in The Netherlands, as
well as in other industrialized countries.1 Chlamydial infections
are often asymptomatic and may therefore remain untreated. In
women, an untreated infection can lead to pelvic inflammatory
disease (PID), chronic pelvic pain, and, at a later stage, to ectopic
pregnancy and tubal factor infertility.2,3 The introduction of
sensitive non-invasive tests and single-dose treatment regimens
has opened the way to large-scale screening for asymptomatic
disease.4–7 Active detection of chlamydial infections, in order to
prevent these complications, has therefore become an import-
ant public health issue.8,9 Screening a population at high risk
for asymptomatic infections has been shown to reduce the
incidence of PID by more than half.3 Furthermore, cost-
effectiveness analyses of studies performed in different settings
suggest that screening becomes cost-effective at prevalences of
2–10%.10–13
These analyses are based on decision models that include
assumptions about the risk of complications, which are derived
from the medical literature. These risks are often estimated on
the basis of populations that are at higher risk of developing
complications, or on the basis of data derived from case-control
studies. The problem with this approach is that the risk can
easily be wrongly estimated, which could lead to under- or over-
estimation of the (cost-) effectiveness of screening. Sensitivity
analyses can be performed to explore the potential impact of
this uncertainty. However, these analyses may not be valid if the
range across which the incidences are varied is incorrect and
does not contain the true population value.
A flawed cost-effectiveness analysis (CEA) may have great
implications for health care policy, resulting in an unjustifiable
implementation of expensive health prevention programmes.
Hence, the purpose of this study is, firstly, to assess the validity
of current assumptions about the probability of developing PID,
tubal factor infertility, ectopic pregnancy, and chronic pelvic
pain after an asymptomatic chlamydial infection. Secondly, to
calculate alternative rates of complications after asymptomatic




A computerized Medline search was carried out to identify
articles published in the international medical literature
(English) between January 1994 and September 2000. Terms
used for the search were ‘cost-effectiveness analysis’ or ‘decision
analysis’ or ‘cost’, and ‘Chlamydia trachomatis’. To be included in
the analysis, the CEA had to report on: (1) a screening
programme aimed at females, (2) a decision model for
asymptomatic C. trachomatis infections, and (3) the estimated
values (and references) for risk of complications after an
asymptomatic infection.
Complications considered in this evaluation were: sub-clinical
PID, clinical PID, tubal factor infertility, ectopic pregnancy, and
chronic pelvic pain. From the CEA we identified the point
estimates for the risk of these complications and, if stated, the
range considered for a sensitivity analysis. The corresponding
references were traced, and evaluated by three of the authors
(IGMvV, SAM, and AJPB) on the design, the interpretation of
the results, and suitability of the source data for estimation of
the risk of complications in the CEA. The aspect of suitability
implies that whilst the study in itself may be valid, it may be
completely unsuitable for the quantification of the risk of
complications after an asymptomatic infection.
Several examples of the problems and inappropriateness
of the source data will be discussed in Results. For
reasons of brevity, not all information from the studies will be
discussed.
Alternative calculation of complication rates
We calculated the probability of complications of C. trachomatis
based on available registration data and data from several (local)
studies. The prevalence of C. trachomatis infections among
women in Amsterdam was derived from a study performed by
Van Valkengoed et al.14 Data on the incidence of clinical PID
were obtained from general practice registers.15 Data on the
occurrence of tubal factor infertility were obtained from Van de
Lisdonk et al.16 Data on the occurrence of ectopic pregnancies
were derived from the National Morbitity and Mortality
Registers.17 The population demographics for Amsterdam were
derived from the official Municipal Population Register.18
Several corrections were made, based on the literature, to
take into account factors such as the number of clinical mis-
diagnoses and non-chlamydia-related episodes of disease.
Finally, the calculated rates for Amsterdam were compared
with the estimated rates, based on the assumptions from the
literature. Furthermore, several of the assumed incidences of
complications in the CEA were compared with reported




We identified five CEA of screening programmes that met the
inclusion criteria. However, only three reported the probabilities
included in the decision models.10,11,19 Two CEA concerned
screening programmes in the US among asymptomatic women
attending a family planning clinic or a sexually transmitted
disease (STD) clinic,10,19 and one concerned a screening
programme in Finland among asymptomatic women attending a
gynaecology and obstetrics clinic.11
Table 1 shows the assumptions for the risk of various
complications after asymptomatic C. trachomatis infection
included in the decision models for these CEA. The estimate for
the total incidence of PID after an asymptomatic C. trachomatis
infection varies from 25% to 80%, including an estimated
10–20% probability of clinical or overt PID.3,10,20–30 One study
reports a sensitivity analysis with a range of 15–40% for all
PID.10 The estimated risk of a clinical and sub-clinical PID 
leading to ectopic pregnancy varies between 5 and 25%.2,21,31–34
A tubal factor infertility is assumed to occur among 10–20% of
all women with a chlamydia-related PID,2,31,35–41 and chronic
pelvic pain among 18–30%.
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Table 1 Evidence for the estimated probabilities of developing complications after Chlamydia trachomatis (CT) infection, used in cost effectiveness analysis (CEA) models for CT screening
programmes
Estimated Predicted CT-
probability of related incidence/
CEA eventsa 10 000 women Target population CEA References Problems or inappropriateness of source data
Marrazzo et al., 1997 PIDb 165 Asymptomatic women Cates, 1991 Review
All: 25%c attending a family Cates, 1993 No diagnostic confirmation ‘asymptomatic’ PID
Clinical: 10% planning clinic or an Cumming, 1988e Diagnosis of PID at time of surgery for EPf, women at
Sub-clinical: 15% STDd clinic, 6.6% high risk
prevalence CT Paavonen, 1985 Women at higher risk, diagnosis CT by serology, women
had several co-infections
Stamm, 1984 PID diagnosis unconfirmed, gonorrhoea is possible cause
for PID, women at high risk
Stamm, 1990 Review
EP 8.3 Cates, 1991 Review
All: 5%g Weström, 1981 Symptomatic women, misclassification
TFIh 16.5 Brunham, 1985 Clinical diagnosis of TFI, serologic diagnosis of CT 
All: 10%i (causal role), case-control data
Cates, 1990 Review
Sellors, 1988 Case-control study, CT diagnosis by detection of 
serological antibodies
Svensson, 1983 Women infected with gonorrhoea
Weström, 1992 Symptomatic cases
CPPj 29.7 Weström, 1980 Symptomatic women, possible biased diagnosis of CPP
All: 18%
Paavonen et al., 1998 PIDb 400 Asymptomatic women Brunham, 1987 Women at higher risk (invasive procedure)
All: 80% attending a gynaecology Cates, 1993 No diagnostic confirmation ‘asymptomatic’ PID
Clinical: 20% and obstetrics clinic, 5% Paavonen, 1985 Women at higher risk, diagnosis CT by serology, women
Sub-clinical: 60% prevalence CT had several co-infections
Platt, 1983 No CT diagnosis, unconfirmed PID
Stamm, 1984 PID diagnosis unconfirmed, Gonorrhoea is possible
cause for PID, women at high risk
Wölner-Hansen, Review
1990
EP 100 Makinen, 1997 Calculation error
All: 25% Weström, 1981 Symptomatic women, misclassification
TFI 80 McCormack, 1994 Review
All: 20% Weström, 1980 Review
Weström, 1994 Symptomatic cases
CPP 120
All: 30%

















































Howell et al., 1998 PID 198 Asymptomatic women Jones, 1986 Women at high risk, no PID diagnosis
All: 30% attending an family Marrazzo, 1997 CEA
Clinical: 12% planning clinic, 6.6% Rees, 1980 Women with gonorrhoea, no chlamydia
Sub-clinical: 18% prevalence CT Scholes, 1996 High risk population, unconfirmed PID
Stamm,1984 PID diagnosis unconfirmed, gonorrhoea is possible cause
for PID, women at high risk
EP 15.5 Haddix, 1995 CEA
All: 7.8% Washington, 1991 No follow-up data
Weström, 1992 Symptomatic women
TFI 23.8 Haddix, 1995 CEA
All: 12% Weström,1992 Symptomatic cases
CPP 35.9 Haddix, 1995 CEA
All: 18.1% Washington, 1991 No follow-up data
a Estimated probabilities of sub-clinical and clinical pelvic inflammatory disease after (a) symptomatic CT infection and ectopic pregnancy/tubal factor infertility/chronic pelvic pain after a pelvic inflammatory
disease.
b Pelvic inflammatory disease.
c A range of 15–40% for all pelvic inflammatory disease considered in sensitivity analysis.
d Sexually transmitted disease.
e Author listed as Cumining in reference list.
f Ectopic pregnancy.
g A range of 5–10% for EP reportedly considered in sensitivity analysis, results not reported.
h Tubal factor infertility.
i A range of 10–20% for TFI is reportedly considered in the sensitivity analysis, results not reported.
j Chronic pelvic pain.
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The evidence
Evidence for the estimates for the occurrence of these
complications is derived from various studies. Several validity
issues are involved:
The population is at greater risk of infection or at greater
risk of developing complications than the population
for which the programme is designed
In one study, women were selected on the basis of a high-risk
profile for STD.3 The circulation of C. trachomatis infections in
this population is probably higher, and they may have already
had multiple infections, which implies that they have a greater
cumulative chance of developing or having developed
complications.42 Moreover, among women who are at high risk
of developing a C. trachomatis infection, the prevalence of other
sexually transmitted pathogens, that may also cause PID, will
most likely also be high.43 In two other studies, the occurrence
of PID among women with clear symptoms of infection
(mucopurulent cervicitis) and women undergoing an abortion
was studied.20,25 It has been well documented that the risk of
PID increases after this type of invasive procedure.44,45
Assumptions are made solely based on case-control data
Several estimates, such as the probability of clinical PID, were
based on case-control studies.21 The odds ratios were
misinterpreted as relative risks, which may lead to over-
estimation of the actual risk. In addition, the absolute risk of
developing PID after a chlamydial infection cannot be derived
from a case-control study.
Diagnosis by exclusion, gaps in the knowledge, and
unsubstantiated assumptions
An example of a gap in the knowledge about C. trachomatis is 
the concept of sub-clinical PID, which has been postulated to
explain the pathway of cervical chlamydial infection to
infertility or ectopic pregnancy, without there being obvious
signs of an infection.46 Sub-clinical PID is mostly diagnosed
retrospectively by exclusion of other possible causes for the
complications; i.e. if there is no evidence of a prior clinical PID,
the PID must have been sub-clinical. For example, in one study,
tubal damage observed among women consulting for (tubal
factor) infertility, who had never had a (self-reported) PID, was
attributed to a previous sub-clinical PID.22 However, women
may not have had a PID or women may just not remember
having experienced a PID.
Moreover, in all the CEA the risk of ectopic pregnancy, tubal
factor infertility, and chronic pelvic pain after sub-clinical PID is
assumed to be equal to the risk after clinical PID. However,
Weström et al. have shown that the risk of developing
complications varies considerably, depending on the severity of
the PID.2 Based on data from their prospective studies, it seems
fair to assume that sub-clinical or mild PID are most likely to
result in lower probabilities of ectopic pregnancy than
symptomatic or severe PID.2
Another issue that needs more attention is chronic pelvic pain.
Only one prospective study is quoted in two CEA to support the
18% probability of chronic pelvic pain.41 (Table 1) This study
refers to Weström et al.,47 who reported that 18.1% of women
with PID reported that they suffered from chronic pelvic pain.
No further (prospective) studies have been performed to
confirm these results.
Misclassification and incorrect diagnoses
C. trachomatis infections, as well as complications, are not or
incorrectly diagnosed in some studies. In one study, the PID rate
among women infected with gonorrhoea was studied, and the
presence of C. trachomatis was not established at all.26 Moreover,
complications were often self-reported or clinically diagnosed
and not confirmed by appropriate diagnostic methods; e.g. the
clinical diagnosis of PID, which cannot be confirmed in
approximately 30% of the cases.48,49 Lastly, misclassification is
also apparent in a study that increases the probability of ectopic
pregnancy after PID by including in the PID group women with
ectopic pregnancy, for whom the damage to the tubes was only
discovered at the time of surgery for ectopic pregnancy.34 This
implies the assumption that all women with PID will develop
ectopic pregnancy. However, the women in the non-ectopic
pregnancy group could also be suffering from undiagnosed PID.
Calculations of the complication rates
An illustrative example of calculation error is the analysis of
Finnish national data by Paavonen et al.11 Despite the fact that
their population does not consist of pregnant women, the
authors use the incidence of ectopic pregnancy per 1000
pregnancies, instead of the lower figure that is given for all
women.32 In addition, applying a tenfold increase in the
number of ectopic pregnancies to account for the increase in
risk after PID does not take into account the fact that the
reported incidence of ectopic pregnancy already includes all
PID-related ectopic pregnancies. This again considerably
overestimates the probability of ectopic pregnancy after PID.
Alternative calculation of complication rates
Figure 1 shows the alternative calculation of the probability of
complications after C. trachomatis infection, based on available
registration data and the prevalence found in Amsterdam, The
Netherlands. In 1997, the prevalence of C. trachomatis infections
among women in Amsterdam was found to be 2.9%.14 The
prevalence was determined in a study based on home-obtained
urine samples from 5714 women randomly selected from
general practice computer registers. According to the Municipal
Population Register, approximately 151 087 women in the age
category 15–40 years lived in Amsterdam,18 and with an
estimated prevalence of 3% it can be calculated that 4556 of
these women have a C. trachomatis infection.
Clinical PID
In Amsterdam, the annual incidence of clinically diagnosed PID
in 1990 was 48.5 per 10 000 woman-years for women aged
15–44 years. More recent data are not available. However,
national surveillance data show a stable incidence in urbanized
areas over the years 1993–1997.15
Only 70% of clinically diagnosed PID can be confirmed
laparoscopically,48,49 resulting in a true incidence of 34 PID per
10 000 women. It is difficult to determine which percentage of
PID is causally related to chlamydial infection. Serological
evidence of C. trachomatis infection is found in approximately
50% of women with PID.21 Not taking into account possible
false-positive or false-negative results, it can be assumed 
that among women with no serological evidence of infection,
the occurrence of a chlamydia-related PID is very unlikely.
Thus, 50% of PID is the maximum number that could
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have been caused by C. trachomatis, resulting in an incidence of
17 PID per 10 000 women, although it must be said that it is
very unlikely that C. trachomatis is actually the (only) causal
agent in all cases. Every year, a total of 257 of clinical PID with
evidence of past C. trachomatis infection will occur in
Amsterdam.
One way of taking into account that women without a
current infection may have had an infection in the past, is to
look at the seroprevalence of chlamydia in women with a
current C. trachomatis infection and women without a current
infection. In a recent Dutch study, serological evidence of C.
trachomatis was found among 70% of women who tested
positive for genital C. trachomatis infection by means of
polymerase chain reaction (PCR) and 26% of women who
tested negative. (personal communication, SAM) Similar results
were reported in a study among Danish women.50 In
Amsterdam, 3189 of the 4556 (70%) women with a genital
C. trachomatis infection and 38 098 of the 146 531 (26%)
women without a genital C. trachomatis infection are
seropositive. Among the total number of 41 287 (3189 + 38
098) women with serological evidence of infection 257 clinical
PID will occur per year: 237 among women without a current
C. trachomatis infection, but with serological evidence of
infection, and 20 among women with a current C. trachomatis
infection and serological evidence of infection. The rate among
4556 women with a current genital infection, of whom 3189
are seropositive at diagnosis, is 0.43%.
Ectopic pregnancy
For ectopic pregnancy, similar calculations can be made.
However, no regional registration data for Amsterdam are
available. Nationwide surveillance systems report an annual
incidence of 2000 ectopic pregnancies,15,17 some of which
occur among women under 15 or over 40 years of age.
Figure 1 Calculation of the probability of pelvic inflammatory disease (a), ectopic pregnancy (b), and tubal factor infertility (c)
A.
Pr{clinical PID | chlamydia }  =   Pr{chlamydia | clinical PID}   *  Pr{clinical PID}
                                                                             Pr{chlamydia} 
Pr{chlamydia}= 0.03 
Pr{clinical PID} = Pr{clinical PID | clinically diagnosed PID}* Pr{clinically diagnosed PID}=0.70*0.00485
Pr{chlamydia | clinical PID}= Pr{chlamydia serology | clinical PID} *                                          Pr{chlamydia}* Pr{chlamydia serology | chlamydia}
                                                                                   Pr{no chlamydia}* Pr{chlamydia serology | no chlamydia}+Pr{chlamydia}* Pr{chlamydia serology | chlamydia}
=   0.50* 0.03*0.70 / (0.97*0.26 + 0.03*0.70) 
(references: 14,15,21,48,49,50,personal communication SAM)
B.
Pr{EP | chlamydia }  =   Pr{chlamydia | EP}   *  Pr{EP}
                                                          Pr{chlamydia} 
Pr{chlamydia}= 0.03 
Pr{EP} =0.0007 
Pr{chlamydia | EP}= Pr{chlamydia serology | EP} *                               Pr{chlamydia}* Pr{chlamydia serology | chlamydia}
                                                                                     Pr{no chlamydia}* Pr{chlamydia serology | no chlamydia}+Pr{chlamydia}* Pr{chlamydia serology | chlamydia}
=   0.40* 0.03*0.70 / (0.97*0.26 + 0.03*0.70) 
(references: 14,16,17,50,51,personal communication SAM)
C.
Pr{TFI | chlamydia }  =   Pr{chlamydia | TFI}   *  Pr{TFI}
                                                          Pr{chlamydia} 
Pr{chlamydia} = 0.03 
Pr{TFI} = Pr{TFI | Subfertility}* Pr{Subfertility} =0.14*0.0020
Pr{chlamydia | TFI} = Pr{chlamydia serology | TFI} *                                          Pr{chlamydia}* Pr{chlamydia serology | chlamydia}
                                                                                        Pr{no chlamydia}* Pr{chlamydia serology | no chlamydia}+Pr{chlamydia}* Pr{chlamydia serology | chlamydia}
=   0.30* 0.03*0.70 / (0.97*0.26 + 0.03*0.70) 
(references: 14,16,50,53,54,personal communication SAM)
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Approximately 2 980 430 women in the age category of 15–40
years live in The Netherlands.17 Assuming that all reported
ectopic pregnancies occur in this age category, it can be deduced
that the annual incidence is 7 per 10 000 woman-years.
However, some of these ectopic pregnancies are not chlamydia-
related. In a previous Dutch study, evidence of prior chlamydial
infection was found in 40% of women with an ectopic
pregnancy.51 The maximum probability of chlamydia-related
ectopic pregnancies is therefore 3 per 10 000 woman-years.
This implies that 42 potentially chlamydiarelated ectopic
pregnancies occur in Amsterdam each year, of which 3.2 occur
among women with a current infection and serological
evidence of C. trachomatis. The rate of ectopic pregnancy among
the women with a current genital infection is 0.07%.
This is the maximum probability of ectopic pregnancy after
C. trachomatis infection, as there are many other causes of
ectopic pregnancy which have not been taken into account.
Finally, probabilities for the entire female population should be
inflated slightly to take into account women who have damaged
tubes, but are not currently seeking pregnancy.
Tubal factor infertility
The estimated incidence of sub-fertility for Amsterdam is 20 per
10 000 woman-years.16 It is estimated that 14–16.5% of these
couples seek specialist medical care for their fertility problem.52
Previous research has also shown that approximately 14% of
infertility is due to a tubal factor:53 an incidence of 2.8 per
10 000 woman-years for Amsterdam. No serological evidence
of chlamydia infection was found in a total of 73% of women
suffering from tubal factor infertility.54 It is therefore assumed
that a maximum of 30% of all tubal factor infertilities are
attributable to C. trachomatis, resulting in an annual incidence of
0.84 per 10 000 women.
Among the 4556 women with C. trachomatis in Amsterdam, of
whom 3189 (70%) have serological evidence of the infection,
0.98 cases of tubal factor infertility will eventually occur. The
maximum probability of tubal factor infertility after chlamydial
infection will then be 0.02%.
If we take into account the fact that approximately 60% of
couples conceive while on a waiting list for treatment,55 thus
indicating that they are not infertile, the probability of tubal
factor infertility after chlamydial infection would be 0.009%.
Finally, these probabilities should be inflated to compensate
for the number of women who have become infertile due to
C. trachomatis, but are not currently seeking pregnancy.
Chronic pelvic pain
Data on chronic pelvic pain diagnoses are not available from
any source.
Calculated versus estimated probabilities
Table 2 shows the calculated probabilities of clinical PID, ectopic
pregnancy, and tubal factor infertility, based on current
assumptions used in the three CEA, and the probabilities
calculated on the basis of the observed occurrence of
complications in Amsterdam. For all complications of C.
trachomatis, the modelled probability is higher than the
probabilities calculated on the basis of registration data from
Amsterdam.
We also compared several estimated rates from the CEA
studies (Table 1) to available data from local registrations
reported in the literature. Firstly, the ectopic pregnancy rates for
Finland. The incidence of ectopic pregnancies (all causes) in
Finland is 15.3 per 10 000 fertile-aged women,32 whereas the
estimated incidence among Finnish women due to C.
trachomatis, using the assumptions from the CEA by Paavonen et
al., was 100 ectopic pregnancies per 10 000.11
Secondly, the rate of PID in the western part and southern
part of the US. In the CEA by Marrazzo et al. (Western US) and
Howell et al. (Southern US), it is estimated that the incidence of
clinical PID due to C. trachomatis is 66 and 79.2 per 10 000
women, respectively.10,19 Rates from a study performed with
data from the 1989–1990 Hospital Discharge Surveys indicate
that in the Western US, the PID rate per 10 000 women of
reproductive age, caused by any agent and not discounted for
potential clinical misdiagnoses, is 34.1. In the Southern US the
total annual incidence is 62.3 per 10 000.56
Lastly, we looked at the estimated rate of ectopic pregnancy
in the CEA from the US. The estimated incidence of ectopic
pregnancy due to a single episode of C. trachomatis in the CEA
was 8.3 (Western) and 15.5 (Southern) per 10 000 women
(Table 1). In 1992, the reported cases of ectopic pregnancies in
the US accounted for approximately 2% of the total number of
pregnancies, a rate of 19.7 per 1000 pregnancies.57 The
reported pregnancy rate per 1000 women in that year was
111.8.58 Thus, the total incidence of ectopic pregnancy is 22.4
Table 2 The estimated probability of complications, calculated on the basis of current assumptions and actual probabilities, based on observed
occurrence of complications in Amsterdam
Estimated based on current assumptions Estimated based on registration data
Probability (%)* Cases due to current CT* Probability (%) Cases due to current CT*
Clinical PID 6–20 274–912 0.43 21
Ectopic pregnancy# 0.75–20 35–912 0.07** 4
Tubal factor infertility# 1.5–16 69–729 0.02*** 1
PID = pelvic inflammatory disease, CT  Chlamydia trachomatis.
# After clinical and sub-clinical PID.
* These ranges were calculated with the minimum and maximum rates presented in the CEAs, including reported sensitivity analysis minimum and maximum
values. Ranges for: all PID 15–80% (9–60% is sub-clinical), ectopic pregnancy 5–25% after PID and tubal factor infertility 10–20% after PID (see Table 1).
** For ectopic pregnancy, national registration data were used instead of data from Amsterdam general practice registers.
*** The probability would be 0.009%, if taking into account the fact that approximately 60% of couples are not infertile, which is apparent from the fact that
they conceive while on a waiting list for treatment.55
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per 10 000 women. Although the estimated incidences due to
C. trachomatis are lower than the observed total incidence, it is
not immediately clear whether the estimated rates are
reasonable, as it is unclear how many of the reported ectopic
pregnancies are chlamydia-related. Unfortunately, the strategy
presented above to determine the rates in Amsterdam could not
be applied, as local data on C. trachomatis antibodies among
women with ectopic pregnancy and among women from the
general population were not available.
Discussion
Literature
Three studies on the cost-effectiveness of screening women for
asymptomatic C. trachomatis infections were reviewed.10,11,19
Estimates for all PID, tubal factor infertility, and ectopic
pregnancy varied from 25–80%, 10–20%, and 5–25%,
respectively. (Table 1) Only one study reported the performance
of a sensitivity analysis for the probabilities of developing
complications.10 However, only the sensitivity analysis for PID
was reported (range 15–40%). When reviewing the supporting
evidence, the general trend was towards a considerable
overestimation of the risk of complications after an
asymptomatic C. trachomatis infection.
The main validity issues encountered were as follows:
—Estimates are based on results from studies carried out in
populations that are at greater risk of infection or at greater
risk of developing complications than the population for
which the programme is designed.
—Several risk assumptions are made solely based on case-
control data. Although they are very useful, it is impossible to
derive absolute risks of complications from these studies.
—At the time of diagnosis of the complication, the occurrence
of the tubal factor infertility or ectopic pregnancy is attributed
to a sub-clinical chlamydial PID, in the absence of any other
apparent cause (diagnosis by exclusion).
—It has also become apparent that there are still great gaps in
current knowledge about the natural course of a chlamydial
infection; gaps that are, at present, filled by unsubstantiated
assumptions.
—Misclassification and incorrect diagnoses. For example,
chlamydia might be considered the cause of the complication,
whilst at the same time it is retrospectively used as an
instrument to diagnose the complication. The clear starting
point of scientists in this field of research is the concept that
C. trachomatis is a serious infection. In some cases, it seems as
if the severity of a C. trachomatis infection is considered to be
almost equal to that of a PID.
—Several mistakes were made in the calculations of the
complication rates.
Alternative complication rates
Probabilities calculated on the basis of modelled estimates were
systematically higher than the probabilities calculated on the
basis of actual data from population registers. The registration
data show that probabilities of clinical PID, ectopic pregnancy,
and tubal factor infertility are much lower than would have been
expected on the basis of current assumptions concerning the
probability of complications after chlamydial infection (Table 2).
Moreover, the comparison of reported and calculated incidences
of ectopic pregnancy and PID in Finland and the US also support
the theory that overestimation of current rates is likely.
For the calculation of the observed rates in Amsterdam, data
from various sources were used. Data on the incidences of PID
and tubal factor infertility were obtained from the Dutch
Sentinel Registration.15,16 The accuracy of these data have been
evaluated by Coutinho et al. in 1988.59 The quality of the data
is high, although some diagnoses might have been missed and
some false-positive diagnoses might have been made.
Furthermore, several assumptions had to be made in the
calculations, which may have resulted in errors. In particular,
the assumption that the national rate of ectopic pregnancy is
similar to the local rate of ectopic pregnancy may be incorrect, as
it is known that the incidence of PID is generally higher in
urbanized areas than in the rest of the country.15 Furthermore,
data on the seroprevalence of C. trachomatis from studies
performed in other regions or countries had to be used, as local
data on the seroprevalence of C. trachomatis in the general
population and among women with complications was not
always available.
However, the difference between the calculated and the
modelled estimates is such that, even if the local seroprevalence
is different and the incidence of complications higher, it seems
fair to assume that current assumptions regarding the risk
of C. trachomatis infections overestimate the probability of
complications.
Sub-clinical PID and chronic pelvic pain were not included in
the calculations for the probability of complications due to
C. trachomatis infections, mainly because chronic pelvic pain and
sub-clinical PID, by definition, are not well documented. The
concept of sub-clinical PID remains difficult to grasp. All the
available evidence is retrospective and diagnosis is ‘by exclusion’.
Therefore, it is very difficult to determine causality and to
quantify the risk. It may be a very helpful concept to promote
the understanding of the pathogenesis of complications with an
otherwise undefined cause, but at the same time it is a poorly
defined and inadequately quantifiable entity for the purpose of
clinical epidemiological studies.
Consequences of the findings
The cost-effectiveness of a screening programme is highly
sensitive to the estimate used for PID.10,60 In populations with
a low prevalence of C. trachomatis, such as general practice
populations or the general population in areas with a low
circulation of infection, the predicted cost savings based on
current assumptions may disappear when using more realistic
estimates for complications.
Cost savings per averted outcome in low prevalence areas will
decrease, making screening less efficient. The effect is perhaps
greatest in populations with a prevalence that lies around or
just above the currently assumed break-even prevalence
(2–10%). Lower probabilities of complications, particularly PID,
imply fewer complications and associated costs that can be
prevented by a screening programme. For those areas, or in
those populations in which the prevalence is high, e.g. in most
STD clinics and gynaecology and obstetrics departments, or
even in pre-defined high-risk sub-groups, the benefits of
screening will be less than presently assumed, but may still be
considerable.
OVERESTIMATION OF COMPLICATIONS IN C. TRACHOMATIS SCREENING 423
 at V
rije U







424 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
In conclusion, current assumptions with regard to the risk of
asymptomatic C. trachomatis infections overestimate the
probability of complications. The result is an overestimation of
the health gain and cost savings associated with a screening
programme. The effect on the health policy is potentially the
greatest in populations with a low prevalence, since the
currently assumed cost savings associated with screening may
disappear when using more realistic estimates for complications.
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KEY MESSAGES
• Current assumptions about the incidence of complications overestimate the true complication rate.
• There are large gaps in knowledge about the natural course of asymptomatic Chlamydia trachomatis infections,
which are, at present, filled by unsubstantiated assumptions.
• The overestimation of complication rates leads to an overestimation of the health gain and cost savings associated
with a screening programme.
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